Management of Contralateral Breast Cancer After Prior Mastectomy

Initial Diagnostic Workup

The American College of Radiology recommends performing diagnostic mammography of the remaining breast to identify the extent of disease and rule out additional lesions 2
Breast MRI may be appropriate as a screening tool for the contralateral breast in patients with prior mastectomy history, as suggested by the Journal of the American College of Radiology 5, 6
Each breast lesion requires independent pathologic confirmation via core needle biopsy before any surgical intervention, according to Praxis Medical Insights 2
The pathologic assessment must include histological type and grade, as recommended by the Annals of Oncology 3, 4, 2
Estrogen receptor (ER) and progesterone receptor (PR) status by immunohistochemistry should be assessed, as suggested by the Annals of Oncology and Praxis Medical Insights 3, 2
HER2 status using FDA-approved companion diagnostic tests should be evaluated, according to the Annals of Oncology and Praxis Medical Insights 4, 2
Ki67 proliferation markers should be assessed, as recommended by Praxis Medical Insights 2
A complete staging workup includes physical examination, complete blood count, routine chemistry, chest imaging, abdominal ultrasound or CT, and bone scan, as suggested by Praxis Medical Insights and the Annals of Oncology 1, 2, 3

The standard surgical approach is total mastectomy of the affected breast with sentinel lymph node biopsy for axillary staging, followed by systemic therapy based on tumor biology, as recommended by Praxis Medical Insights 1, 2
Sentinel lymph node biopsy is the standard of care for axillary staging when invasive cancer is present, according to the Annals of Oncology and Praxis Medical Insights 3, 4, 1, 2
Immediate breast reconstruction is appropriate and should be discussed with all patients, as suggested by the Annals of Oncology and Praxis Medical Insights 3, 4, 1, 2
Breast conservation therapy is feasible only when specific criteria are met, including clear surgical margins, tumor size relative to breast volume, absence of multicentric disease, and no prior chest wall irradiation, as recommended by the Annals of Oncology and Praxis Medical Insights 4, 3, 2

Treatment decisions must be based on the biological characteristics of the new cancer, considering tumor stage, hormone receptor status, HER2 status, and axillary lymph node involvement, as recommended by Praxis Medical Insights 1, 2
For hormone receptor-positive tumors, endocrine therapy is mandatory, and aromatase inhibitors are alternatives for postmenopausal women, as suggested by Praxis Medical Insights 2
For HER2-positive tumors, anti-HER2 therapy plus chemotherapy is recommended, according to Praxis Medical Insights 2
For triple-negative tumors, chemotherapy is the mainstay, and immunotherapy should be considered if PD-L1 positive, as recommended by Praxis Medical Insights 2

Post-mastectomy radiation therapy is recommended for patients with four or more positive axillary nodes, T3-T4 tumors, or one to three positive axillary lymph nodes with additional risk factors, as suggested by the Annals of Oncology 3
Post-mastectomy radiation therapy should be considered for patients with one to three positive axillary lymph nodes, according to the Annals of Oncology and Praxis Medical Insights 3, 2

BRCA1/2 carriers face a 25-31% 10-year risk of developing new breast cancer, as reported by the Annals of Oncology 4
With bilateral mastectomy, the risk for subsequent breast cancer incidence is reduced by 90-95%, according to the Annals of Oncology and Praxis Medical Insights 4, 2
Risk-reducing salpingo-oophorectomy should be considered per genetic/familial high-risk assessment guidelines, as recommended by the Annals of Oncology and Praxis Medical Insights 4, 1, 2

Annual clinical examinations of the chest/reconstructed breast are recommended after bilateral mastectomy, as suggested by Praxis Medical Insights 1, 2
Mammograms are not recommended after bilateral mastectomy, according to Praxis Medical Insights 1, 2
Focus surveillance on detection of locoregional recurrence, systemic metastases, and routine health maintenance, as recommended by the Annals of Oncology and Praxis Medical Insights 4, 1